ChiCTR2100044585 版本V1.3 版本创建时间2021/09/19 13:34:39 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2100044585 

最近更新日期:

Date of Last Refreshed on:

2021-09-19 13:31:08 

注册时间:

Date of Registration:

2021-03-24 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

针刺治疗坐骨神经痛的随机对照临床研究

Public title:

Efficacy of acupuncture for sciatica: a randomized controlled trial

注册题目简写:

English Acronym:

研究课题的正式科学名称:

针刺治疗坐骨神经痛的随机对照临床研究

Scientific title:

Efficacy of acupuncture for sciatica: a randomized controlled trial

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiMCTR2100004623

申请注册联系人:

于芳婷 

研究负责人:

刘存志 

Applicant:

Fang-Ting Yu 

Study leader:

Cun-Zhi Liu 

申请注册联系人电话:

Applicant telephone:

+86 10-53912201

研究负责人电话:

Study leader's
telephone:

+86 10-53912201

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

1026943645@qq.com

研究负责人电子邮件:

Study leader's E-mail:

lcz_tg@126.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

北京市朝阳区北三环东路11号

研究负责人通讯地址:

北京市朝阳区北三环东路11号

Applicant address:

11 North Third Ring Road East, Chaoyang District, Beijing

Study leader's address:

11 North Third Ring Road East, Chaoyang District, Beijing

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

北京中医药大学针灸推拿学院

Applicant's institution:

School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese Medicine

研究负责人所在单位:

北京中医药大学针灸推拿学院

Affiliation of the Leader:

School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2020BZYLL0803

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

北京中医药大学医学伦理委员会

Name of the ethic committee:

Ethics Committee of Beijing University of Chinese Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2020-12-16 00:00:00

伦理委员会联系人:

秦灵灵

Contact Name of the ethic committee:

Ling-Ling Qin

伦理委员会联系地址:

北京市朝阳区北三环东路11号

Contact Address of the ethic committee:

11 North Third Ring Road East, Chaoyang District, Beijing

伦理委员会联系人电话:

Contact phone of the ethic committee:

010-53911431

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

北京中医药大学

Primary sponsor:

Beijing University of Chinese Medicine

研究实施负责(组长)单位地址:

北京市朝阳区北三环东路11号

Primary sponsor's address:

11 North Third Ring Road East, Chaoyang District, Beijing

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

省(直辖市):

市(区县):

Country:

Province:

City:

单位(医院):

具体地址:

Institution
hospital:

Address:

经费或物资来源:

国家重点研发计划中医药现代化研究重点专项(项目编号:2019YFC1712101)

Source(s) of funding:

National Key R&D Program of China(Project Number:2019YFC1712101)

研究疾病:

坐骨神经痛  

Target disease:

sciatica

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

评价针刺治疗坐骨神经痛的疗效和安全性  

Objectives of Study:

The purpose of this study is to verify the efficacy and safety for acupuncture in treating discogenic sciatica.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

(1)年龄≥18岁,男女不限;
(2)符合坐骨神经痛诊断标准
(3)病程>3个月;
(4)腿痛视觉模拟评分(VAS)≥40mm;
(5)签署知情同意书。

Inclusion criteria

(1)Patients 18 years or older
(2)Patients meeting the diagnostic criteria of sciatica
(3)Sciatica lasting for more than 3 months
(4)Intensity of leg pain on visual analogue scale(VAS) over 40mm
(5)Patients who are willing to sign the informed consent

排除标准:

(1)由腰椎间盘突出症以外的原因导致的坐骨神经痛;
(2)已知或怀疑脊柱严重病理状况(如马尾综合征)或严重进行性神经症状(如进行性肌无力);
(3)存在心、肝、肾功能异常,或造血系统疾病、精神疾病,或者其他严重并存疾病(如癌症);
(4)怀孕、哺乳或试验期间有怀孕计划;
(5)正在服用对坐骨神经痛有治疗作用的药物;
(6)过去1年内接受过腰椎间盘手术治疗;
(7)试验治疗期内计划进行脊柱手术或其他介入治疗(如注射糖皮质激素);
(8)过去1年内使用过针灸治疗坐骨神经痛。

Exclusion criteria:

(1)Sciatica caused by other conditions than lumar disc herniation
(2)Patients who have or are suspected to have severe spinal disease (e.g., cauda equina syndrome) or severe progressive neurological symptoms (e.g., progressive muscle weakness)
(3) Patients with cardiovascular, liver, kidney, or hematopoietic system diseases, mental health disorders, or other severe coexisting diseases (e.g., cancer)
(4)Patients who are pregnant, breast-feeding or planning to conceive during the trial
(5)Patients who are taking drugs that have a therapeutic effect on sciatica
(6)Patients who underwent surgery for lumbar disc herniation within the past 1 year
(7)Patients who plan to have a spinal surgery or other interventional treatments (e.g., epidural steroid injection) during the treatment period of the trial
(8)Patients who have received acupuncture for treating sciatica within the past 1 year

研究实施时间:

Study execute time:

From 2021-03-01 00:00:00 To 2022-09-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2021-04-01 00:00:00 To 2021-09-01 00:00:00

干预措施:

Interventions:

组别:

针刺组

样本量:

108

Group:

Acupuncture group

Sample size:

干预措施:

手针

干预措施代码:

Intervention:

manual acupuncture

Intervention code:

组别:

假针组

样本量:

108

Group:

Sham-acupuncture group

Sample size:

干预措施:

假针刺

干预措施代码:

Intervention:

sham acupuncture

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

北京中医药大学东直门医院 

单位级别:

三级甲等 

Institution
hospital:

Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

中国中医科学院广安门医院 

单位级别:

三级甲等 

Institution
hospital:

Guang'anmen Hospital Affiliated to the China Academy of Chinese Medical Sciences Medicine

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

北京大学第三医院 

单位级别:

三级甲等 

Institution
hospital:

Peking University Third Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

江苏省 

市(区县):

 

Country:

China

Province:

Jiangsu province

City:

单位(医院):

南京中医药大学附属医院 

单位级别:

三级甲等 

Institution
hospital:

Affiliated Hospital of Nanjing University of Traditional Chinese Medicine

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

湖北省 

市(区县):

 

Country:

China

Province:

Hubei province

City:

单位(医院):

华中科技大学同济医学院附属协和医院 

单位级别:

三级甲等 

Institution
hospital:

Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

深圳 

市(区县):

 

Country:

China

Province:

Shenzhen

City:

单位(医院):

北京中医药大学深圳医院 

单位级别:

三级甲等 

Institution
hospital:

Shenzhen Hospital, Beijing University of Chinese Medicine

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

腿部疼痛强度较基线变化值

指标类型:

主要指标

Outcome:

Change of leg pain intensity from baseline

Type:

Primary indicator

测量时间点:

随机分组后第4周

测量方法:

视觉模拟评分法(VAS)

Measure time point of outcome:

Week 4 after randomization

Measure method:

visual analogue scale(VAS)

指标中文名:

Oswestry功能障碍指数较基线变化值

指标类型:

主要指标

Outcome:

Change of scores on Oswestry disability index from baseline

Type:

Primary indicator

测量时间点:

随机分组后第4周

测量方法:

Oswestry功能障碍量表

Measure time point of outcome:

Week 4 after randomization

Measure method:

Oswestry disability index

指标中文名:

其他时间点腿痛较基线变化值

指标类型:

次要指标

Outcome:

Change of leg pain intensity from baseline at other evaluation time points

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

腰痛较基线变化值

指标类型:

次要指标

Outcome:

Change of back pain intensity from baseline

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

其他时间点Oswestry功能障碍指数较基线变化值

指标类型:

次要指标

Outcome:

Change of scores on Oswestry disability index from baseline at other evaluation time points

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

坐骨神经痛频率与不适指数

指标类型:

次要指标

Outcome:

Sciatica Frequency and Bothersomeness Index

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

健康调查简表(SF-36)

指标类型:

次要指标

Outcome:

Short Form Health Survey 36

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

应急药物与其他治疗的使用

指标类型:

次要指标

Outcome:

The use of rescue medicine or other treatment methods

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

不良事件发生率

指标类型:

次要指标

Outcome:

Incidence of adverse events

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

整体恢复自我评分

指标类型:

次要指标

Outcome:

Global perceived recovery

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

可信度评价

指标类型:

次要指标

Outcome:

Credibility assessment

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

盲法评价

指标类型:

次要指标

Outcome:

Blinding assessment

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

脑磁共振成像

指标类型:

次要指标

Outcome:

brain magenetic resonance imaging

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

NA

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

采用中心区组随机方法通过统计学软件生成随机序列。

Randomization Procedure (please state who generates the random number sequence and by what method):

This trial will use central block randomization method produced by statistical analysis software.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

本试验对受试者、数据收集/录入者和统计人员设置盲法

Blinding:

Patients, outcome assessor and statistician will be blinded to the assignments.

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

试验完成后6个月内,通过中国临床试验注册中心的ResMan平台进行原始数据的共享(http://www.medresman.org.cn.)

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Within 6 months after the trial complete, we will share IPD based on the ResMan platform (http://www.medresman.org.cn.)

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

通过电子采集和管理系统记录数据。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

The records of metadata are recorded through Electronic Data Capture.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2021-03-24 04:12:07